Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis
Open Access
- 27 June 2016
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 9 (8) , 1025-1037
Abstract
Introduction: Few innovative anti-microbial products have been brought to market in recent years to combat the global multidrug resistant-tuberculosis (MDR-TB) epidemic. Bedaquiline, a novel oral diarylquinoline, was approved by the US FDA as a part of combination therapy in adults with pulmonary MDR-TB based on phase II trials. Area covered: Pubmed searches were conducted using search terms bedaquiline, diarylquinoline, R207910, and TMC207 was performed. Supplementary sources included World Health Organization, Clinicaltrial.gov, US Food and Drug Administration. Bedaquiline is an ATP synthase inhibitor specific for M. tuberculosis and some nontuberculous mycobacteria. It is metabolized by CYP3A4 and it’s drug exposure can be influenced by inducers and inhibitors of this enzyme. Phase II studies showed promising results on efficacy of bedaquiline when being used in combination with a background regimen for MDR-TB. Main safety concerns include QTc prolongation and hepatotoxicity. Phase III trials are ongoing to confirm efficacy findings from phase II studies and provide additional evidence of safety and efficacy. Expert commentary: Critical data for long-term efficacy and safety are incomplete and scarce, supporting the cautious use of bedaquiline.Keywords
This publication has 55 references indexed in Scilit:
- Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug ResistanceAntimicrobial Agents and Chemotherapy, 2012
- Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy VolunteersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Pharmacokinetics and Pharmacodynamics of TMC207 and Its N -Desmethyl Metabolite in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Rates and Mechanisms of Resistance Development inMycobacterium tuberculosisto a Novel Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2007
- Synergistic Activity of R207910 Combined with Pyrazinamide against Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2007
- Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment DurationAntimicrobial Agents and Chemotherapy, 2006
- Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in MycobacteriaAntimicrobial Agents and Chemotherapy, 2006